Neurologic Manifestations of Whipple Disease Workup
- Author: George C Bobustuc, MD; Chief Editor: Karen L Roos, MD more...
Laboratory Studies
- Routine laboratory values are often abnormal. Initial laboratory studies routinely obtained include the following:
- Baseline CBC with differential, platelets, and erythrocyte indexes
- Electrolytes - Sodium, potassium, chloride, calcium, magnesium, iron
- Vitamin levels (usually folate and vitamin B-12 with its metabolic derivatives, homocysteine and methylmalonic acid); thiamin (vitamin B-1), pyridoxine (vitamin B-6), and carotene (provitamin A) levels may help identify rapidly reversible deficits and rule out alternative diagnoses.
- Other baseline labs should target some of the differential diagnosis variants and include rapid plasma reagent and HIV testing, erythrocyte sedimentation rate, complement C3 and C5, antinuclear antibody, and angiotensin-converting enzyme levels. Also obtain baseline liver function tests, thyroid function tests, and random cortisol level. Extend endocrinologic workup (free testosterone, luteinizing hormone, follicle-stimulating hormone) on an individual basis to rule out pituitary gland or, more commonly, hypothalamic involvement.
- Nonspecific results supportive of steatorrhea include decreased serum cholesterol and carotene levels, decreased iron levels, elevated prothrombin time, and low serum albumin as a result of a combination of the protein-losing enteropathy, decreased absorption of amino acids, and decreased hepatic synthesis.
- Multifactorial normocytic hypochromic anemia is present in 90% of patients and is caused by chronic infection and malabsorption with decreased iron, vitamin B-12, and folate.
- Not infrequently, thrombocytosis is present with counts of greater than 1 million/mL. This may be the basis for a hyperviscosity syndrome (with exacerbation of cardiac disease and stroke). Both anemia and thrombocytosis reverse with specific antibiotic treatment for Whipple disease.
Imaging Studies
- Radiology
- Of patients with Whipple disease with GI upset, 85% have abnormal results on upper GI series. More than 50% of these patients present with bowel dilation with or without prominent mucosal folds of the duodenum and jejunum. In 60% of these patients, flocculation and segmentation of barium also is reported.
- Other findings include dilatation of the proximal ileum, stomach with thickened nodular folds, and possibly edema of the colon on barium enema. All of these findings are nonspecific; they also may be found in other diseases such as celiac sprue and lymphoma.
- Various imaging studies reveal enlarged retroperitoneal and mediastinal lymph nodes in 10% of patients with Whipple disease.
- Neuroimaging: Neuroimaging is largely nonspecific. CT scan and MRI with and without contrast may reveal nondiagnostic abnormalities including atrophy, hydrocephalus, mass lesions with contrast enhancement, ring-enhancing lesions, and other focal changes, including white matter changes with no mass effect, suggesting demyelination.
Other Tests
- Specific tests for malabsorption and biliary salts metabolism
- Specific tests indicative of steatorrhea (90% of patients with Whipple disease have malabsorption) include qualitative or 72-hour quantitative stool analysis and absorption of D-xylose (with decreased fractional absorption detected by low serum and urinary levels).[13]
- Bile salt metabolism testing reveals an increase in the deoxycholic acid-to-cholic acid ratio after intravenous challenge with taurocholate (ie, the inverse of the normal response).
- Electrodiagnostic testing
- No diagnostic/specific EEG pattern has been described for CNS-WD. EEG may be normal, show focal or generalized slow wave activity, or identify irritative foci with spike activity.
- Electromyography (EMG) of the muscles involved in OFSM has revealed 400-millisecond bursts of bilateral rhythmic activity. The activity originates from the level of CN VII and spreads rostrally to involve the muscles of mastication and caudally to involve muscles of the neck, arms, and legs.
- Cerebrospinal fluid studies
- CSF is frequently abnormal (high protein, > 5 WBC, intrathecal synthesis of IgA). In patients who carry a diagnosis of Whipple disease, nonspecific inflammatory markers in CSF have been reported as useful surrogates to monitor response and durability of remission. More specific testing of the CSF is required for a positive diagnosis, such as PAS staining, EM, and PCR.
- CSF PCR should be considered in all patients with Whipple disease; as it gains acceptance as a useful tool for assessing CNS involvement, it represents the most sensitive tool in evaluating response to antibiotic treatment and early detection of relapse.[18] Termination of a long course antibiotic treatment in a patient with Whipple disease who experienced a good clinical response should be based ultimately on CSF PCR analysis alone.
Procedures
The diagnosis of Whipple disease is made by demonstrating characteristic lesions in tissue obtained from biopsy of significant organs (defined as organs usually known to be involved in Whipple disease and responsible for some of the complaints and/or signs noted on examination).
- Plan significant organ biopsy with PAS staining, EM analysis, and PCR of the tissue sample.
- For patients with GI complaints, peroral GI biopsy should be the initial diagnostic method of choice. It reveals foamy macrophages containing PAS-positive, gram-positive bacilli in the lamina propria of the mucosa of the small intestine.
- Studies reviewing patients with Whipple disease and GI complaints revealed only a 50% sensitivity of multiple (2-3) peroral GI biopsies. The review of patients with CNS-WD revealed a higher sensitivity of 70%, which is due in part to a sampling effect, since these patients are less likely to be diagnosed with CNS-WD without a positive peroral GI biopsy.
- Consider all patients with CNS-WD for a peroral GI biopsy as part of their initial diagnostic workup.
- PAS-positive macrophages in the lamina propria of the colon and rectum are nondiagnostic, since they have been reported in healthy people and in patients with histiocytosis, melanosis coli, or pneumatosis intestinales.
- PAS-positive macrophages in lymph node biopsy alone, not corroborated by other significant tissue biopsy results, is not diagnostic, since this can be a common finding in tuberculosis, sarcoidosis, Gaucher disease, and berylliosis.
- Lumbar puncture: CNS involvement can be demonstrated quite well with CSF analysis; PAS staining of cellular material may be adequate, or the diagnosis may be confirmed with PCR when PAS staining is inconclusive.
- Brain biopsy[19] is a last resort in a patient with a nonspecific focal lesion amenable to biopsy in whom the diagnosis cannot be made by testing other sites (eg, GI biopsy) or by CSF analysis.
Histologic Findings
Macrophages containing PAS-positive, gram-positive bacilli have been found in various body tissues of patients with Whipple disease, including heart and heart valves, CNS and CSF, lung, spleen, Kupffer cells (ie, cells with functional role of macrophages in the liver), pancreas, muscle, bone marrow, kidney, lymph nodes, and synovial membranes.
- The PAS-positive material found in macrophages represents remnants of the cell walls of the phagocytosed bacilli. These bacilli stain gram positive and acid-fast negative. Whipple disease bacillus has a distinct wall and an outer capsule and measures approximately 0.5-1.5 mm. These bacilli, despite typically being regarded as intracellular pathogens, also have been found as PAS-positive, rod-shaped bacteria in the extracellular environment.
- CNS-WD has a predilection for the periaqueductal gray matter, hypothalamus, hippocampus, basal ganglia, cerebellum, and cerebral cortex. Whipple disease bacillus usually is found at the site of involvement along with a specific inflammatory response.
- The gross pathologic features of CNS-WD are generalized atrophy and small, chalky nodules or granulomas as large as 2 mm in diameter scattered diffusely in the grey matter of the cerebral and cerebellar hemispheres and in the periventricular and periaqueductal regions. The changes are patchy and usually are surrounded by totally normal areas of the brain.
- The involvement of periaqueductal gray matter is thought to be responsible for hydrocephalus observed in some patients.
- The microscopic appearance of the granulomatous changes reveals strongly PAS-positive macrophages surrounded by large reactive astrocytes. In more advanced cases, the PAS-positive cellular infiltrate may extend in the white matter and may be associated with demyelination and neuronal death with formation of large vacuoles; with more severe extension, the PAS-positive infiltrate may burst into the subarachnoid space. All strongly PAS-positive areas of the brain reveal specific trilamellar appearance of T whippelii bacilli and bacillary debris on EM.
Whipple GH. A hitherto undescribed disease characterized anatomically by deposits of fat and fatty acids in the intestinal and mesenteric lymphatic tissues. Johns Hopkins Hosp Bull. 1907;18:382-391.
Black-Schaffer B. The tinctorial demonstration of a glycoprotein in Whipple's disease. Proc Soc Exp Biol Med. 1949;72:225.
Paulley JW. A case of Whipple's disease (intestinal lipodystrophy). Gastroenterology. 1952;22:128-33.
Keinath RD, Merrell DE, Vlietstra R, Dobbins WO 3rd. Antibiotic treatment and relapse in Whipple's disease. Long-term follow-up of 88 patients. Gastroenterology. Jun 1985;88(6):1867-73. [Medline].
Wilson KH, Blitchington R, Frothingham R, Wilson JA. Phylogeny of the Whipple's-disease-associated bacterium. Lancet. Aug 24 1991;338(8765):474-5. [Medline].
Relman DA, Schmidt TM, MacDermott RP, Falkow S. Identification of the uncultured bacillus of Whipple's disease. N Engl J Med. Jul 30 1992;327(5):293-301. [Medline].
Ramzan NN, Loftus E, Burgart LJ, et al. Diagnosis and monitoring of Whipple disease by polymerase chain reaction. Ann Intern Med. Apr 1 1997;126(7):520-7. [Medline].
Raoult D, Birg ML, La Scola B, Fournier PE, Enea M, Lepidi H, et al. Cultivation of the bacillus of Whipple's disease. N Engl J Med. Mar 2 2000;342(9):620-5. [Medline].
Raoult D, Ogata H, Audic S. Tropheryma whipplei Twist: a human pathogenic Actinobacteria with a reduced genome. Genome Res. Aug 2003;13(8):1800-9. [Medline].
Raoult D, Ogata H, Audic S, et al. Tropheryma whipplei Twist: a human pathogenic Actinobacteria with a reduced genome. Genome Res. Aug 2003;13(8):1800-9. [Medline].
Bentley SD, Maiwald M, Murphy LD, Pallen MJ, Yeats CA, Dover LG, et al. Sequencing and analysis of the genome of the Whipple's disease bacterium Tropheryma whipplei. Lancet. Feb 22 2003;361(9358):637-44. [Medline].
Dorman SE, Holland SM. Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev. Dec 2000;11(4):321-33. [Medline].
Fenollar F, Laouira S, Lepidi H, Rolain JM, Raoult D. Value of Tropheryma whipplei quantitative polymerase chain reaction assay for the diagnosis of Whipple disease: usefulness of saliva and stool specimens for first-line screening. Clin Infect Dis. Sep 1 2008;47(5):659-67. [Medline].
Bonhomme CJ, Renesto P, Nandi S, Lynn AM, Raoult D. Serological microarray for a paradoxical diagnostic of Whipple's disease. Eur J Clin Microbiol Infect Dis. Oct 2008;27(10):959-68. [Medline].
Panegyres PK, Foster JK, Fallon M, Connor C. The amnesic syndrome of primary Whipple disease of the brain. Cogn Behav Neurol. Mar 2010;23(1):49-51. [Medline].
Schwartz MA, Selhorst JB, Ochs AL, Beck RW, Campbell WW, Harris JK, et al. Oculomasticatory myorhythmia: a unique movement disorder occurring in Whipple's disease. Ann Neurol. Dec 1986;20(6):677-83. [Medline].
Brandle M, Ammann P, Spinas GA, Dutly F, Galeazzi RL, Schmid C, et al. Relapsing Whipple's disease presenting with hypopituitarism. Clin Endocrinol (Oxf). Mar 1999;50(3):399-403. [Medline].
von Herbay A, Ditton HJ, Schuhmacher F, Maiwald M. Whipple's disease: staging and monitoring by cytology and polymerase chain reaction analysis of cerebrospinal fluid. Gastroenterology. Aug 1997;113(2):434-41. [Medline].
De Coene B, Gilliard C, Indekeu P, Duprez T, Trigaux JP. Whipple's disease confined to the central nervous system. Neuroradiology. May 1996;38(4):325-7. [Medline].
Le Scanff J, Gaultier JB, Durand DV, Durieu I, Celard M, Benito Y, et al. [Tropheryma whipplei and Whipple disease: false positive PCR detections of Tropheryma whipplei in diagnostic samples are rare]. Rev Med Interne. Nov 2008;29(11):861-7. [Medline].
Seneca V, Imperato A, Colella G, Cioffi V, Mariniello G, Gangemi M. Recurrent acute obstructive hydrocephalus as clinical onset of cerebral Whipple's disease. Clin Neurol Neurosurg. Oct 2010;112(8):717-21. [Medline].
Adams M, Rhyner PA, Day J, DeArmond S, Smuckler EA. Whipple's disease confined to the central nervous system. Ann Neurol. Jan 1987;21(1):104-8. [Medline].
Benito-León J, Sedano LF, Louis ED. Isolated central nervous system Whipple's disease causing reversible frontotemporal-like dementia. Clin Neurol Neurosurg. Jul 2008;110(7):747-9. [Medline].
Clarke CE, Falope ZF, Abdelhadi HA, Franks AJ. Cervical myelopathy caused by Whipple's disease. Neurology. May 1998;50(5):1505-6. [Medline].
Comer GM, Brandt LJ, Abissi CJ. Whipple's disease: a review. Am J Gastroenterol. Feb 1983;78(2):107-14. [Medline].
Cooper GS, Blades EW, Remler BF, Salata RA, Bennert KW, Jacobs GH. Central nervous system Whipple's disease: relapse during therapy with trimethoprim-sulfamethoxazole and remission with cefixime. Gastroenterology. Mar 1994;106(3):782-6. [Medline].
Dobbins WO 3rd. The diagnosis of Whipple's disease. N Engl J Med. Feb 9 1995;332(6):390-2. [Medline].
Fenollar F, Birg ML, Gauduchon V. Culture of Tropheryma whipplei from human samples: a 3-year experience (1999 to 2002). J Clin Microbiol. Aug 2003;41(8):3816-22. [Medline].
Fenollar F, Fournier PE, Robert C. Use of genome selected repeated sequences increases the sensitivity of PCR detection of Tropheryma whipplei. J Clin Microbiol. Jan 2004;42(1):401-3. [Medline].
Knox DL, Green WR, Troncoso JC, Yardley JH, Hsu J, Zee DS. Cerebral ocular Whipple's disease: a 62-year odyssey from death to diagnosis. Neurology. Apr 1995;45(4):617-25. [Medline].
Kowalczewska M, Villard C, Lafitte D, Fenollar F, Raoult D. Global proteomic pattern of Tropheryma whipplei: a Whipple's disease bacterium. Proteomics. Mar 2009;9(6):1593-616. [Medline].
Louis ED, Lynch T, Kaufmann P, Fahn S, Odel J. Diagnostic guidelines in central nervous system Whipple's disease. Ann Neurol. Oct 1996;40(4):561-8. [Medline].
Lynch T, Odel J, Fredericks DN, Louis ED, Forman S, Rotterdam H, et al. Polymerase chain reaction-based detection of Tropheryma whippelii in central nervous system Whipple's disease. Ann Neurol. Jul 1997;42(1):120-4. [Medline].
Marth T, Neurath M, Cuccherini BA, Strober W. Defects of monocyte interleukin 12 production and humoral immunity in Whipple's disease. Gastroenterology. Aug 1997;113(2):442-8. [Medline].
Marth T, Roux M, von Herbay A, Meuer SC, Feurle GE. Persistent reduction of complement receptor 3 alpha-chain expressing mononuclear blood cells and transient inhibitory serum factors in Whipple's disease. Clin Immunol Immunopathol. Aug 1994;72(2):217-26. [Medline].
Masselot F, Boulos A, Maurin M. Molecular evaluation of antibiotic susceptibility: Tropheryma whipplei paradigm. Antimicrob Agents Chemother. May 2003;47(5):1658-64. [Medline].
Moos V, Kunkel D, Marth T, Feurle GE, LaScola B, Ignatius R, et al. Reduced peripheral and mucosal Tropheryma whipplei-specific Th1 response in patients with Whipple's disease. J Immunol. Aug 1 2006;177(3):2015-22. [Medline].
Pollock S, Lewis PD, Kendall B. Whipple's disease confined to the nervous system. J Neurol Neurosurg Psychiatry. Dec 1981;44(12):1104-9. [Medline].
Richardson DC, Burrows LL, Korithoski B, Salit IE, Butany J, David TE, et al. Tropheryma whippelii as a cause of afebrile culture-negative endocarditis: the evolving spectrum of Whipple's disease. J Infect. Aug 2003;47(2):170-3. [Medline].
Ryser RJ, Locksley RM, Eng SC, Dobbins WO 3rd, Schoenknecht FD, Rubin CE. Reversal of dementia associated with Whipple's disease by trimethoprim-sulfamethoxazole, drugs that penetrate the blood-brain barrier. Gastroenterology. Apr 1984;86(4):745-52. [Medline].
Sanavro SM, Voerman HJ. Whipple's disease: easily diagnosed, if considered. Neth J Med. Mar 2009;67(3):108. [Medline].
Schneider T, Stallmach A, von Herbay A. Treatment of refractory Whipple disease with interferon-gamma. Ann Intern Med. Dec 1 1998;129(11):875-7. [Medline].
Schnider P, Trattnig S, Kollegger H, et al. MR of cerebral Whipple disease. AJNR Am J Neuroradiol. Jun-Jul 1995;16(6):1328-9. [Medline].
Sloan LM, Rosenblatt JE, Cockerill FR. Detection of Tropheryma whipplei DNA in clinical specimens by LightCycler real-time PCR. J Clin Microbiol. Jul 2005;43(7):3516-8. [Medline].
Swartz MN. Whipple's disease--past, present, and future. N Engl J Med. Mar 2 2000;342(9):648-50. [Medline].
Wilson KH. New vistas for bacteriologists: analysis based on 16S rRNA sequences provides a rapid and reliable approach to the identity of human pathogens. ASM News. 1992;58:318-21.

